Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain.
METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response.
RESULTS: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group.
CONCLUSION: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.
Details
Original language | English |
---|---|
Pages (from-to) | 1131-1137 |
Number of pages | 7 |
Journal | Multiple Sclerosis Journal |
Volume | 28 |
Issue number | 7 |
Early online date | 7 Jan 2022 |
Publication status | Published - Jun 2022 |
Peer-reviewed | Yes |
External IDs
PubMedCentral | PMC9131404 |
---|---|
Scopus | 85122656213 |
ORCID | /0000-0001-8799-8202/work/171553568 |
Keywords
Sustainable Development Goals
Keywords
- Antibodies, Viral, COVID-19 Vaccines, COVID-19/prevention & control, Humans, Immunity, Immunoglobulin G, Multiple Sclerosis/drug therapy, SARS-CoV-2, Technology, Vaccination, Vaccines, Synthetic, mRNA Vaccines